We acknowledge that the Australian Government fully fund the Australian Red Cross Blood Service for the provision of blood products and services to the Australian Community.
An 8-week course of 45 mg of carbonyl iron daily reduces iron deficiency in female whole blood donors aged 18 to 45 years: results of a prospective randomized controlled trial
Article first published online: 28 OCT 2013
© 2013 American Association of Blood Banks
Special Issue: Donating Blood: Who? Why? What of It?
Volume 54, Issue 3pt2, pages 780–788, March 2014
How to Cite
Marks, D. C., Speedy, J., Robinson, K. L., Brama, T., Capper, H. R., Mondy, P. and Keller, A. J. (2014), An 8-week course of 45 mg of carbonyl iron daily reduces iron deficiency in female whole blood donors aged 18 to 45 years: results of a prospective randomized controlled trial. Transfusion, 54: 780–788. doi: 10.1111/trf.12464
- Issue published online: 11 MAR 2014
- Article first published online: 28 OCT 2013
- Manuscript Accepted: 25 AUG 2013
- Manuscript Revised: 15 AUG 2013
- Manuscript Received: 2 MAY 2013
- Australian Government
Blood donation is known to contribute to iron deficiency in regular blood donors. This study investigated the safety and efficacy of postdonation iron replacement to mitigate iron deficiency in blood donors.
Study Design and Methods
A total of 282 female whole blood donors aged 18 to 45 were prospectively randomized in a double-blinded placebo controlled trial to receive an 8-week postdonation course of carbonyl iron (45 mg daily) or placebo. The primary endpoint was prevalence of iron deficiency (ferritin < 15 ng/mL) at 12 weeks postdonation. Secondary endpoints were eligibility to donate based on capillary hemoglobin (Hb) and incidence of gastrointestinal (GI) complaints.
Ferritin levels at Week 12 were significantly higher in donors receiving carbonyl iron (17.0 ± 10.9 ng/mL) compared with those receiving placebo (10.6 ± 8.4 ng/mL; p < 0.001). The proportion of iron-deficient donors was significantly lower in the carbonyl iron group (51.9%) compared to the placebo (80.5%; p < 0.001). The mean Hb level in the carbonyl iron group (134.6 ± 8.7 g/L) was significantly higher than in the placebo arm (130.0 ± 9.9 g/L; p < 0.001), significantly improving eligibility to donate at Week 12. Significantly more donors receiving carbonyl iron had at least one GI side effect (p < 0.001). Importantly, 86.7% of donors receiving carbonyl iron indicated that they would take iron on an ongoing basis.
An 8-week postdonation course of 45 mg of carbonyl iron significantly reduced iron deficiency and was well tolerated in female whole blood donors. Postdonation iron replacement may have a role in a broader strategy to optimize donor iron status.